Willemieke S Tummers1,2, Sarah E Miller3, Nutte T Teraphongphom3, Adam Gomez4, Idan Steinberg1, David M Huland1, Steve Hong3, Sri-Rajasekhar Kothapalli1, Alifia Hasan3, Robert Ertsey3, Bert A Bonsing2, Alexander L Vahrmeijer2, Rutger-Jan Swijnenburg2, Teri A Longacre4, George A Fisher5, Sanjiv S Gambhir6, George A Poultsides7, Eben L Rosenthal8,9. 1. Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, CA, USA. 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Otolaryngology, Stanford University, Stanford, CA, USA. 4. Department of Pathology, Stanford University, Stanford, CA, USA. 5. Department of Medical Oncology, Stanford University, Stanford, CA, USA. 6. Departments of Radiology, Bioengineering, and Materials Science & Engineering, Molecular Imaging Program at Stanford; Canary Center at Stanford for Early Cancer Detection, Stanford University, Stanford, CA, USA. 7. Department of Surgery, Stanford University, Stanford, CA, USA. 8. Department of Otolaryngology, Stanford University, Stanford, CA, USA. elr@stanford.edu. 9. Stanford Cancer Center, Stanford University, Stanford, CA, USA. elr@stanford.edu.
Abstract
BACKGROUND: Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor. METHODS: A dose-escalation study was performed to assess safety and feasibility of targeting and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence and photoacoustic imaging ex vivo. RESULTS: Seven patients with resectable pancreatic masses suspected to be PDAC were enrolled in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 ± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding tissue. CONCLUSIONS: The safety and feasibilty of intraoperative, tumor-specific detection of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and metastases was demonstrated.
BACKGROUND: Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor. METHODS: A dose-escalation study was performed to assess safety and feasibility of targeting and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence and photoacoustic imaging ex vivo. RESULTS: Seven patients with resectable pancreatic masses suspected to be PDAC were enrolled in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 ± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding tissue. CONCLUSIONS: The safety and feasibilty of intraoperative, tumor-specific detection of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and metastases was demonstrated.
Authors: Jeannine Bachmann; Christoph W Michalski; Marc E Martignoni; Markus W Büchler; Helmut Friess Journal: HPB (Oxford) Date: 2006 Impact factor: 3.647
Authors: Arja Gerritsen; I Quintus Molenaar; Thomas L Bollen; C Yung Nio; Marcel G Dijkgraaf; Hjalmar C van Santvoort; G Johan Offerhaus; Lodewijk A Brosens; Katharina Biermann; Egbert Sieders; Koert P de Jong; Ronald M van Dam; Erwin van der Harst; Harry van Goor; Bert van Ramshorst; Bert A Bonsing; Ignace H de Hingh; Michael F Gerhards; Casper H van Eijck; Dirk J Gouma; Inne H M Borel Rinkes; Olivier R C Busch; Marc G Besselink Journal: Ann Surg Oncol Date: 2014-05-29 Impact factor: 5.344
Authors: Merlijn Hutteman; Hak Soo Choi; J Sven D Mieog; Joost R van der Vorst; Yoshitomo Ashitate; Peter J K Kuppen; Marian C van Groningen; Clemens W G M Löwik; Vincent T H B M Smit; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Ann Surg Oncol Date: 2010-11-16 Impact factor: 5.344
Authors: Israt S Alam; Idan Steinberg; Ophir Vermesh; Nynke S van den Berg; Eben L Rosenthal; Gooitzen M van Dam; Vasilis Ntziachristos; Sanjiv S Gambhir; Sophie Hernot; Stephan Rogalla Journal: Mol Imaging Biol Date: 2018-10 Impact factor: 3.488
Authors: Willemieke S Tummers; Eben L Rosenthal; Alexander L Vahrmeijer; George A Poultsides Journal: Ann Surg Oncol Date: 2018-10-12 Impact factor: 5.344
Authors: Madeline T Olson; Nicholas E Wojtynek; Geoffrey A Talmon; Thomas C Caffrey; Prakash Radhakrishnan; Quan P Ly; Michael A Hollingsworth; Aaron M Mohs Journal: Mol Cancer Ther Date: 2020-05-13 Impact factor: 6.261
Authors: Suman B Mondal; Christine M O'Brien; Kevin Bishop; Ryan C Fields; Julie A Margenthaler; Samuel Achilefu Journal: J Nucl Med Date: 2020-04-17 Impact factor: 10.057
Authors: Allison S Cohen; Jun Li; Matthew R Hight; Eliot McKinley; Allie Fu; Adria Payne; Yang Liu; Dawei Zhang; Qing Xie; Mingfeng Bai; Gregory D Ayers; Mohammed Noor Tantawy; Jarrod A Smith; Frank Revetta; M Kay Washington; Chanjuan Shi; Nipun Merchant; H Charles Manning Journal: Clin Cancer Res Date: 2020-09-15 Impact factor: 12.531